NOVAPIO
15MG TBL NOB 30
| Maximum ex-factory price/Ex-factory price ? | 445,97 CZK |
|---|---|
| Legal basis of maximum ex-factory price/ex-factory price ? | Maximum ex-factory price announced under the law. |
Informace o základní úhradě
| Core reimbursement from health insurance ? | 145,22 CZK |
|---|---|
| Maximum reimbursement from health insurance ? | 215,99 CZK |
| Legal basis of reimbursement from health insurance ? | Reimbursement set by the law. |
| Indication restriction of reimbursement ? | Pioglitazon je hrazen pro léčbu diabetes mellitus 2. typu u pacientů s klinicky zřetelně manifestovanou inzulinovou rezistencí. Léčba je ukončena, pokud nedojde do 6 měsíců k prokazatelnému zlepšení kompenzace diabetu léčbou pioglitazonem (pokles hodnoty HbA1c nejméně o 10 %). V kombinaci s inzulinem nebo inzulinem a metforminem je pioglitazon hrazen při preskripci lékařem s odborností v oboru diabetologie (DIA). |
| Prescribing doctor's specialisation ? | – |
| Reporting limit ? | – |
| Rough price for the final consumer ? | 644,60 CZK |
| Rough payment for the final consumer (for 1 prescribed package dispensed) ? | 428.61 CZK |
| Eligible extra payment ? | 50,18 CZK |
| Eligible extra payment for individuals aged 65 and older ? | 50,18 CZK |
cz